Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
The SCO Summit 2026 is scheduled to feature leaders and representatives of the Shanghai Cooperation…
India Post is making an upgrade to its digital services by launching upgraded versions of…
The Statue of Liberty is among the world's well-known symbols of freedom, democracy, and friendship.…
Satish Golcha, who had earlier served as the Commissioner of Police for Delhi, has been…
India and China are agreed to continue dialogue which aimed at to finding a just,…
Fino Payments Bank granted another three months extension to Ketan Merchant, who shall act as…